Al18F-NOTA-octreotide(Al18F-NOTA-octreotide) - 药物靶点：SSTR_专利_临床

概要

基本信息

药物类型

多肽偶联核素、诊断用放射药物

别名

靶点

SSTR

作用机制

SSTR拮抗剂(生长抑素受体拮抗剂)、PET imaging(正电子发射断层成像术增强剂)

治疗领域

肿瘤

在研适应症-

非在研适应症

神经内分泌肿瘤

原研机构

Universitaire Ziekenhuizen Leuven

在研机构-

非在研机构

Universitaire Ziekenhuizen Leuven

最高研发阶段无进展临床2/3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

使用我们的ADC技术数据为新药研发加速。

登录

或

查看完整样例数据

关联

3

项与 Al18F-NOTA-octreotide 相关的临床试验

NCT04552847 / Completed临床2/3期IIT

Al18F-NOTA-octreotide PET Imaging of the Somatostatin Receptor in Neuroendocrine Tumors

The aim of this study is to evaluate the diagnostic performance of Al18F-NOTA-octreotide PET imaging in comparison with the current golden standard, 68Ga-DOTA-somatostatin analog PET, in neuroendocrine tumor patients.

开始日期2020-10-07

申办/合作机构

Universitaire Ziekenhuizen Leuven

[+2]

NCT03883776 / Completed临床1期IIT

Al18F-NOTA-octreotide PET Imaging of the Somatostatin Receptor in Neuroendocrine Tumors: a First-in-human PET/CT Study

The aim of this study is to evaluate the potential of Al18F-1,4,7-triazacyclononane-1,4,7-triacetate-octreotide (Al18F-NOTA-octreotide) as a positron emission tomography (PET) somatostatin receptor imaging agent in patients with neuroendocrine tumors.

开始日期2019-04-11

申办/合作机构-

NCT03511768 / Unknown status临床1/2期IIT

A Study of 18F-AlF-NOTA-octreotide PET/CT for Imaging Neuroendocrine Neoplasms

The aim of this study is to investigate the clinical value of [18F]aluminum fluoride-1,4,7-triazacyclononane-1,4,7-triacetic acid-octreotide（18F-AlF-NOTA-octreotide ） positron emission tomography / computed tomography (PET/CT) in patients with neuroendocrine neoplasms (NENs).

开始日期2018-01-02

申办/合作机构

中南大学湘雅三医院

100 项与 Al18F-NOTA-octreotide 相关的临床结果

登录后查看更多信息

100 项与 Al18F-NOTA-octreotide 相关的转化医学

登录后查看更多信息

100 项与 Al18F-NOTA-octreotide 相关的专利（医药）

登录后查看更多信息

14

项与 Al18F-NOTA-octreotide 相关的文献（医药）

2024-04-18·Hellenic journal of nuclear medicine

Al¹⁸F-NOTA-Octreotide outperforms ¹⁸F-FDG in identifying rare renal metastases from pancreatic neuroendocrine tumor.

Article

作者: Diao, Wei ; Kou, Ying ; Ye, Zhenyan ; Cheng, Zhuzhong

We presented a case involving a 56-year-old man who had been experiencing shoulder and back pain for over a year, with extensive bone metastases revealed by a bone scan. To identify the primary source of these issues, the patients underwent a fluorine-18-fluorodeoxyglucose (¹⁸F-FDG) positron emission tomography/computed tomography (PET/CT) scan, which indicated moderate uptake in the right renal soft mass and low uptake in multiple osteolytic lesions. Pathological examination and immunohistochemical staining of the renal mass supported the diagnosis of neuroendocrine tumors. Subsequently, a novel somatostatin receptor imaging agent, Al¹⁸F-NOTA-octreotide (¹⁸F-OC), was performed to further investigate the source of metastatic lesions and to stage the tumor. The ¹⁸F-OC scan revealed a high-uptake lesion in the pancreatic head, as well as additional lymph node and bone metastases lesions.Compared to ¹⁸F-FDG, the ¹⁸F-OC demonstrated superior imaging capabilities and a significantly higher tumor-to-background ratio in neuroendocrine neoplasms, which contributed to improvingthe staging and treatment management.

2024-03-01·Clinical Nuclear Medicine

Al18F-NOTA-Octreotide PET/CT and 18F-FDG PET/CT for Detecting Cerebellar Hemangioblastoma in a Patient With Von Hippel-Lindau Disease

Article

作者: Wang, Xuejuan ; Hou, Guozhu ; Cheng, Xin ; Zheng, Rong ; Chi, Yihebali

AbstractVon Hippel-Lindau disease is a hereditary syndrome associated with various benign and malignant tumors, including hemangioblastomas. A 42-year-old man with a history of Von Hippel-Lindau disease underwent surgery for pancreatic neuroendocrine tumor and renal clear cell carcinoma and was recommended to undergo Al18F-NOTA-octreotide and 18F-FDG PETCT examination to assess potential metastases. 18F-FDG PET/CT showed low uptake in the right cerebellum, which demonstrated increased Al18F-NOTA-octreotide activity. Cerebellar mass resection surgery was performed. Pathological result was consistent with hemangioblastoma. This case report indicates the significant role of Al18F-NOTA-octreotide in the diagnosis of hemangioblastoma.

2023-02-01·Nuclear Medicine Communications

A novel urokinase plasminogen activator receptor-targeted peptide-based probe for in-vivo molecular imaging of glioblastoma

Article

作者: Sun, Ziyan ; Han, Yunfeng ; Xu, Liying ; Tu, Le ; Zhang, Yongxue

AimThe urokinase plasminogen activator receptor (uPAR) is a promising biomarker for cancer diagnosis and therapy. We herein fabricated a new type of uPAR-targeted imaging probe Al18F-NOTA-VC and preliminarily evaluated its potential application in PET imaging of the glioma model in vivo.MethodsPeptide VC was synthesized and identified by MALDI-TOF-MS. The IC50 between VC/precursor NOTA-VC and uPAR was then determined before the synthesis and purification of Al18F-NOTA-VC, followed by further studies of in-vitro properties of Al18F-NOTA-VC. Meanwhile, the AE105-based probe followed a similar procedure in-vitro test. Finally, the PET imaging properties, including uPAR-targeting ability and the metabolism of Al18F-NOTA-VC, were investigated.ResultsThe VC and NOTA-VC were obtained successfully and demonstrated a good affinity with uPAR. Followed by Al18F labeling successfully, excellent properties, including the serum stability, water solubility, and specificity of Al18F-NOTA-VC, were obtained in-vitro test compared with AE105 based probe. An excellent tumor uptake and renal excretion data of Al18F-NOTA-VC were acquired from in-vivo U87MG tumor model PET imaging, consistent with the subsequent biodistribution study.ConclusionIn addition to the excellent specificity and high tumor/normal tissue contrast for uPAR-targeted PET imaging of U87MG tumor, Al18F-NOTA-VC possessed promising clearance ability by renal system route. These excellent properties facilitated Al18F-NOTA-VC to be a promising imaging agent for uPAR high-expressing tumors and, thus, provided a paradigm for developing peptide-based probes for uPAR-associated disease diagnosis.

100 项与 Al18F-NOTA-octreotide 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
神经内分泌肿瘤	临床3期	比利时	Universitaire Ziekenhuizen Leuven	2020-10-07

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


SNMMI2024	N/A	神经内分泌肿瘤	-	18F-AlF-NOTA-octreotide PET/CT	窪繭鏇淵憲築窪觸鑰艱(簾鹹夢鬱選願齋鹽壓顧) = 製糧鏇獵鑰蓋製夢鑰觸鹹製鏇觸繭壓餘憲鏇窪 (製夢餘憲鹹艱顧蓋選廠 ) 更多	-	2024-06-09
				18F-AlF-NOTA-octreotide (Contrast-enhanced CT/MRI)	窪繭鏇淵憲築窪觸鑰艱(簾鹹夢鬱選願齋鹽壓顧) = 壓範選觸襯壓艱醖齋襯鹹製鏇觸繭壓餘憲鏇窪 (製夢餘憲鹹艱顧蓋選廠 ) 更多